1. Combination Chemotherapy in Advanced Adrenocortical Carcinoma
- Author
-
Fassnacht, M., Terzolo, M., Allolio, B., Baudin, E., Haak, H., Berruti, A., Welin, S., Schade Brittinger, C., Lacroix, A., Jarzab, B., Sorbye, H., Torpy, D. J., Stepan, V., Schteingart, D. E., Arlt, W., Kroiss, M., Leboulleux, S., Sperone, P., Sundin, A., Hermsen, I., Hahner, S., Willenberg, H. S., Tabarin, A., Quinkler, M., De La Fouchardiere, C., Schlumberger, M., Mantero, F., Weismann, D., Beuschlein, F., Gelderblom, H., Wilmink, H., Sender, M., Edgerly, M., Kenn, W., Fojo, T., Muller, H. H., Skogseid, B., Haaf, M., Johanssen, S., Koschker, A. C., Laubner, K., Sbiera, S., Schiemann, J., Wortmann, S., Haase, M., Schott, M., Möhlig, M., Zopf, K., Reisch, N., Betz, M., Reincke, M., Isermann, B., Bornstein, S., Fottner, C., Bose, A., Petersenn, S., Leitolf, H., Klose, S., Wolf, H., Chougnet, C., More, J., Nunes, M. L., Droz, J. P., Nicolli, P., Chabre, O., Clergeot, A., Schillo, F., Penfornis, A., Do Cao, C., Goldwasser, F., Rodien, P., Ferrero, A., Perotti, P., Cicala Mv, Anna P., Della Casa, S., Mannelli, M., Piccini, V., Dercksen, M. W., Romijn, J. A., Ouwerkerk, J., Devries, J. H., Eriksson, B., Janson, E. T., Granberg, D., Oberg, K., Ahlman, H., Garkavij, M., Wall, N., Falkmer, U., Hammer, G., Olney, H. J., Bourdeau, I., Bourque, L., Szpak Ulczok, S., Jarzab, M., Holte, H., Fossa, A., Ploner, F., Mansmann, U., Schmoll, H. J., Simonsson, B., Toscano, Vincenzo, Petersenn, Stephan (Beitragende*r), CCA -Cancer Center Amsterdam, Oncology, Other departments, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, General Internal Medicine, and Endocrinology
- Subjects
Adult ,Male ,adrenal tumor ,medicine.medical_specialty ,Medizin ,Kaplan-Meier Estimate ,Gastroenterology ,Disease-Free Survival ,Streptozocin ,Young Adult ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Adrenocortical Carcinoma ,Medicine ,Adrenocortical carcinoma ,Humans ,Mitotane ,Adverse effect ,Etoposide ,Aged ,Intention-to-treat analysis ,business.industry ,Medicine (all) ,Hazard ratio ,Combination chemotherapy ,General Medicine ,Middle Aged ,medicine.disease ,Adrenal Cortex Neoplasms ,Surgery ,Intention to Treat Analysis ,Regimen ,Doxorubicin ,Cisplatin ,Female ,Quality of Life ,business ,medicine.drug - Abstract
A b s t r ac t Background Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. Methods We randomly assigned 304 patients with advanced adrenocortical carcinoma to re ceive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg per square meter on day 1), and cisplatin (40 mg per square meter on days 3 and 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g on days 1 to 5 in cycle 1; 2 g on day 1 in subsequent cycles) every 3 weeks. Patients with disease progression received the alternative regimen as second-line therapy. The primary end point was overall survival. Results For first-line therapy, patients in the EDP–mitotane group had a significantly higher response rate than those in the streptozocin–mitotane group (23.2% vs. 9.2%, P
- Published
- 2012
- Full Text
- View/download PDF